B

BioXcel Therapeutics
D

BTAI

2.13000
USD
-0.22
(-9.36%)
مغلق
حجم التداول
2,705
الربح لكل سهم
-10
العائد الربحي
-
P/E
-0
حجم السوق
6,606,853
نظرة عامةالتوصياتالأفكار والتحليلاتالأخبار
أصول ذات صلة
    B
    BLUE
    -2.93000
    (-41.68%)
    4.10000 USD
    C
    CRSP
    -2.620
    (-5.19%)
    47.840 USD
    E
    EDIT
    -0.14000
    (-6.80%)
    1.92000 USD
    GILD
    GILD
    -0.140
    (-0.13%)
    109.920 USD
    MRK
    MRK
    1.820
    (2.08%)
    89.500 USD
    N
    NTLA
    -0.075
    (-0.61%)
    12.180 USD
    PFE
    PFE
    0.405
    (1.56%)
    26.305 USD
    REGN
    REGN
    4.37
    (0.63%)
    700.66 USD
    S
    SGMO
    -0.04500
    (-4.00%)
    1.08000 USD
    المزيد
الأخبار
المقالات

العنوان: BioXcel Therapeutics Inc

القطاع: Healthcare
الصناعة: Biotechnology
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology.The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.